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ABSTRACT
Pyruvate kinase isoform M2 (PKM2) converts phospho-
enolpyruvate (PEP) to pyruvate and plays an important
role in cancer metabolism. Here, we show that post-
translational modiﬁcations and a patient-derived muta-
tion regulate pyruvate kinase activity of PKM2 through
modulating the conformation of the PKM2 tetramer. We
determined crystal structures of human PKM2 mutants
and proposed a “seesaw” model to illustrate confor-
mational changes between an inactive T-state and an
active R-state tetramers of PKM2. Biochemical and
structural analyses demonstrate that PKM2Y105E (phos-
phorylation mimic of Y105) decreases pyruvate kinase
activity by inhibiting FBP (fructose 1,6-bisphosphate)-
induced R-state formation, and PKM2K305Q (acetylation
mimic of K305) abolishes the activity by hindering tet-
ramer formation. K422R, a patient-derived mutation of
PKM2, favors a stable, inactive T-state tetramer because
of strong intermolecular interactions. Our study reveals
the mechanism for dynamic regulation of PKM2 by post-
translational modiﬁcations and a patient-derived muta-
tion and provides a structural basis for further investi-
gation of other modiﬁcations and mutations of PKM2 yet
to be discovered.
KEYWORDS pyruvate kinase M2, crystal structure,
allosteric regulation, Warburg effect, post-translational
modiﬁcations
INTRODUCTION
Most somatic cells produce energy predominantly through
oxidative phosphorylation, whereas cancer cells produce
energy mainly through the less efﬁcient glycolytic pathway,
followed by lactic acid production under aerobic conditions
(Warburg, 1956). This aerobic glycolysis (also known as the
Warburg effect) plays an important role in tumorigenesis
(Vander Heiden et al., 2009; Koppenol et al., 2011; Chaneton
and Gottlieb, 2012; Yang and Lu, 2013; Wong et al., 2015).
Pyruvate kinase transfers one phosphate group from phos-
phoenolpyruvate (PEP) to adenosine di-phosphate (ADP),
and thus generates one pyruvate molecule and one aden-
osine tri-phosphate (ATP) molecule. This step is one of the
rate-limiting steps of glycolysis, and therefore pyruvate
kinase is one of the primary mediators of glycolysis.
Four mammalian isoforms of pyruvate kinase-PKL, PKR,
PKM1 and PKM2-are expressed in various types of cells and
tissues. PKL is expressed in the liver, and PKR is expressed in
the redbloodcells.PKM1andPKM2arederived fromalternative
splicing of the PKM gene (Noguchi et al., 1986; Noguchi et al.,
1987). PKM1 is a constitutively active isoform expressed in dif-
ferentiated cells from various tissues. In contrast, PKM2 has low
basal activity and is activated by an effector molecule fructose
1,6-bisphosphate (FBP). PKM2 is expressed in most proliferat-
ing cells (Christofk et al., 2008a). Furthermore, the regulation of
PKM2 pyruvate kinase activity plays an essential role in cancer
metabolism and is crucial for the growth and survival of cancer
cells (Chaneton and Gottlieb, 2012; Yang and Lu, 2013; Wong
et al., 2015). Recently, PKM2 has been reported to function as a
nuclear protein kinase to regulate gene transcription and pro-
mote tumorigenesis (Gao et al., 2012; Yang et al., 2012a, b;Gao
et al., 2013; Lv et al., 2013; Keller et al., 2014).
PKM2 exists in a dynamic population of monomer, dimer
and tetramer and its pyruvate kinase activity relies on the
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formation of the tetramer. Upon formation of the tetramer,
PKM2 can adopt the inactive T-state or active R-state con-
formation (Morgan et al., 2013). The pyruvate kinase activity
of PKM2 is regulated by metabolic intermediates and post-
translational modiﬁcations. For example, metabolic inter-
mediates such as FBP and N-succinyl-5-aminoimidazole-4-
carboxamide ribose-5′-phosphate (SAICAR) increase the
pyruvate kinase activity of PKM2 (Dombrauckas et al., 2005;
Chaneton et al., 2012; Keller et al., 2012). Synthetic com-
pounds have been screened for their ability to activate PKM2
and, thus, suppress cancer growth (Boxer et al., 2010; Jiang
et al., 2010; Anastasiou et al., 2012; Kung et al., 2012).
Some of these compounds have been shown to promote
tetramer formation of PKM2 and enhance its enzymatic
activity (Anastasiou et al., 2012). In addition, serine and
phenylalanine have been reported to bind to the allosteric
site of PKM2 and activate or inhibit its activity, respectively
(Chaneton et al., 2012; Morgan et al., 2013).
Post-translational modiﬁcations including phosphoryla-
tion, oxidation, hydroxylation and acetylation also regulate
PKM2 activity to promote cancer proliferation. For example,
acetylation of residue K305 inhibits pyruvate kinase activity
of PKM2 in vitro (Lv et al., 2011) and acetylation of residue
K433 affects FBP binding and prevents PKM2 activation (Lv
et al., 2013). Phosphorylation of residue Y105 inhibits the
tetramer formation and pyruvate kinase activity of PKM2
(Hitosugi et al., 2009). Furthermore, oxidation of residue
C358 inhibits PKM2 activity and promotes the metabolic
changes required for proliferation (Anastasiou et al., 2011).
PKM2 hydroxylation of P403 and P408 promotes HIF-1
transactivation in cancer cells (Luo et al., 2011). The muta-
tion R399E of PKM2 (PKM2R399E) was shown to disrupt the
tetramer formation on one of dimer interfaces, thereby pro-
ducing dimers and decreasing its pyruvate kinase activity
(Gao et al., 2012). In addition, mutations K422R and H391Y
of PKM2 (PKM2K422R and PKM2H391Y) were shown to
decrease its pyruvate kinase activity in Bloom Syndrome
(BS) patients, who are prone to cancer (Anitha et al., 2004;
Akhtar et al., 2009; Gupta et al., 2010; Iqbal et al., 2014).
Although PKM2 has been studied for decades, how its
activity is regulated remains poorly understood. In this study,
we revealed how pyruvate kinase activity of PKM2 is regu-
lated by post-translational modiﬁcations and a patient-
derived mutation. On the basis of our observations, we
propose a model for dynamic regulation of PKM2. Our study
also provides a structural basis for further investigation of
dynamic regulation of PKM2 by other post-translational
modiﬁcations and mutations involved in cancer metabolism.
RESULTS
Effects of post-translational modiﬁcations
and a patient-derived mutation on PKM2 activity
To investigate how the enzymatic activity of PKM2 is regu-
lated, we puriﬁed wild-type PKM2 (PKM2WT), PKM2R399E (a
dimeric mutant) (Gao et al., 2012) and PKM2K422R (a patient-
derived mutation). Given the difﬁculty to obtain phosphory-
lated or acetylated PKM2 proteins, we puriﬁed PKM2Y105E (a
phosphorylation mimic of Y105) and PKM2K305Q (an acety-
lation mimic of K305) to mimic PKM2 containing the two
modiﬁcations. The above four PKM2 mutants and PKM2WT
were used for enzymatic activity assays and structural
studies (Fig. S1A). We ﬁrst measured the enzymatic activi-
ties for wild-type and mutants of PKM2 and calculated the
Km values for PEP. The kinetic activities were calculated
based on the PEP saturation curves in the absence or pre-
sence of FBP, an allosteric activator of PKM2 (Fig. 1A and
1B). We also calculated the normalized pyruvate kinase
activity (kcat/Km, (mol/L)−1 s−1), as represented by the value
of Vmax/Km of PKM2WT, because an equal amount of pro-
tein was used for all activity assays (Fig. 1C). We could not
detect protein kinase activity for human PKM2 under our
experimental conditions using histone H3 as substrate (data
not shown). Therefore, only pyruvate kinase activities
(enzymatic activity hereafter if not speciﬁed) were measured
for wild-type and mutants of PKM2. A high enzyme con-
centration in the reaction would greatly decrease the accu-
racy of calculated reaction rate. Because of the extremely
fast reaction rate (less than 1.5 min), we measured the
pyruvate kinase activity in nanomolar concentrations.
In the presence of FBP, PKM2WT showed a signiﬁcant
increase in enzymatic activity (compared to that in the
absence of FBP) with a normalized kcat/Km of 5.6 and a
decrease in Km to 0.2 mM (Fig. 1A–C and Table S1).
PKM2K305Q showed barely detectable pyruvate kinase
activity in the absence of FBP, and a normalized kcat/Km of
0.2 in the presence of FBP, indicating a signiﬁcant decrease
in activity. Compared to PKM2WT, PKM2R399E showed a
decrease in activity in the absence or presence of FBP, with
a kcat/Km of 0.6 or 1.8, respectively. Interestingly,
PKM2Y105E showed a slight decrease in activity in the pre-
sence, but not the absence, of FBP, with a kcat/Km of 1.2 in
the absence of FBP and 4.3 in the presence of FBP. In
contrast, PKM2K422R signiﬁcantly decreased the enzymatic
activity (kcat/Km of 0.2) and substrate binding afﬁnity only in
the absence of FBP. Taken together, these mutations
showed different effects on pyruvate kinase activity of PKM2.
Enzymatic activities of PKM2 mutants are not positively
correlated with PKM2 tetramer formation
Tetramer formation is essential for the pyruvate kinase
activity of PKM2 (Dombrauckas et al., 2005). The gel-ﬁltra-
tion analyses of wild-type and mutants of PKM2 show a
mixed population of PKM2 in monomer, dimer and tetramer
(Figs. 1D, 1E and S1B). PKM2WT appears to preferentially
form a dimer in the absence of FBP and tends to form a
tetramer in the presence of FBP. Compared to PKM2WT,
PKM2Y105E and PKM2R399E showed similar patterns of
oligomerization in the absence of FBP. In contrast,
RESEARCH ARTICLE Ping Wang et al.









PKM2K305Q tended to form a monomer whereas PKM2K422R
mainly formed a tetramer in the absence of FBP. In the
presence of FBP, PKM2Y105E and PKM2R399E only slightly
increased their tendency to form a tetramer, whereas
PKM2K305Q only formed a dimer; PKM2K422R maintained its
tendency to form the tetramer. The above observations are
generally consistent with the prediction that the more tetra-
mer that forms, the more active the protein is. However,
exceptions exist. For example, in the absence of FBP,
PKM2K422R showed a signiﬁcantly high level of tetramer
formation, but was much less active than PKM2WT. The
results indicate that tetramer formation alone cannot explain
how PKM2 activity is regulated by these mutations.
It was also noted that PKM2WT formed a tetramer in a
concentration- and time-dependent manner (Fig. S1C and
S1D). As indicated by size exclusive chromatography, the
higher concentration of protein used, the more tetramer
formed (Fig. S1C). Interestingly, monomeric PKM2 eluted
when either tetrameric or monomeric PKM2 was re-sub-
jected to size exclusion chromatography under similar
experimental conditions (Fig. S1D). To minimize concentra-
tion- and time-dependent confounding factors, we compared
the oligomerization states of PKM2WT and all the mutants
under similar protein concentrations and experimental
conditions.
Enzymatic activities of PKM2 mutants are not positively
correlated with their thermal stability
The thermal stability of PKM2 was reported to reﬂect its
enzymatic activity (Morgan et al., 2010). Thus, we next
performed a thermal-shift assay to investigate the correlation
PEP (mmol/L)
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Figure 1. Activities and tetramer formation for wild-type PKM2 and mutants of PKM2. (A and B) Kinetic activities of PKM2
proteins in the absence (A) or presence (B) of FBP. The data were ﬁt with the Allosteric Sigmoidal Equation (A) or the Michaelis-
Menten Equation (B). (C) Normalized activities (kcat/Km) of wild-type PKM2 and mutants of PKM2 calculated according to the results
from Fig. 1A and 1B with the value (kcat/Km) of PKM2WT as a standard. The error bars represent mean ± SD for triplicate
experiments. (D and E). Gel ﬁltration of wild-type and mutants of PKM2 in the absence (D) or presence (E) of FBP. Peak positions of
monomer, dimer and tetramer are indicated as dashed lines. The color scheme for PKM2 proteins is indicated. Superdex 200 (GE
Healthcare, 10/300 GL) was used in gel-ﬁltration analyses.
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between enzymatic activity and thermal stability of PKM2
proteins. PKM2WT and PKM2Y105E showed two peaks (Tm:
∼44°C and ∼60°C) in the absence of FBP and a single peak
(Tm value of ∼59°C) in the presence of FBP (Fig. S1E, Table
S1). Compared to PKM2WT, PKM2K305Q was less stable in
the absence (Tm: ∼44°C) and presence (Tm: ∼54°C) of FBP,
which is consistent with its lesser tendency toward tetramer
formation and lower enzymatic activity. The Tm values of
PKM2R399E (∼ 56°C) and PKM2K422R (∼ 61°C) were slightly
enhanced by the addition of FBP, indicating that both pro-
teins are relatively stable and FBP could not signiﬁcantly
enhance their thermal stabilities. These results indicate that
thermal stability is not positively correlated with enzymatic
activity or tetramer formation of the wild-type and mutants of
PKM2 tested in this study. Taken together, the above results
indicate that changes of the pyruvate kinase activity of PKM2
could not be predicted based on the state of oligomerization
or thermal stability.
Crystal structures of human PKM2 mutants
To investigate the molecular mechanism for the regulation of
PKM2 activity, we determined the crystal structures of
PKM2K305Q, PKM2Y105E, PKM2R399E and PKM2K422R in the
absence of FBP, in addition to PKM2K422R in the presence of
FBP (PKM2K422R_FBP) (Fig. S2A and Table 1). Although
PKM2WT and PKM2 mutants (except PKM2K422R) were
present in the form of a monomer in a certain percentage in
solution with low protein concentration (less than 0.2 mg/mL)
(Fig. 1D), all PKM2 proteins formed tetramer in the crystals.
The results are consistent with the observation that higher
protein concentration leads to more tetramer formation for
PKM2 proteins in gel ﬁltration (Fig. S1C). The crystal struc-
tures of wild-type PKM2 in the presence of oxalate
(PKM2Oxalate) (PDB: 3BJT) (Christofk et al., 2008b) and
PKM2 in complex with phenylalanine (PKM2Phe) (PDB:
4FXJ) (Morgan et al., 2013) were used for the following
structural comparison. In addition, we drafted a model for
four monomers in the tetramer structure to clarify the fol-
lowing description (Fig. S2A).
The ﬁrst striking observation from the structural analyses
is that PKM2Oxalate, PKM2K305Q and PKM2K422R_FBP adop-
ted the R-state conformation, whereas all other PKM2
mutants adopted the T-state conformation (Fig. S2A).
Notably, phenylalanine was previously reported to function
as an inhibitor to lock PKM2 in an inactive T-state confor-
mation (Morgan et al., 2013). PKM2Oxalate adopted an
R-state conformation because the crystals were obtained in
the presence of oxalate (an analog of PEP), which may
induce an R-state conformation of PKM2 (Christofk et al.,
2008b). Similarly, PKM2K305Q adopted an R-state confor-
mation because the protein was crystallized in the presence
of malonate (0.2 mol/L), which was observed in the active
site of the PKM2K305Q structure (Fig. S2B). Both oxalate and
malonate are analogs of PEP and may favor the formation of
the R-state tetramer. These results suggest that wild-type
PKM2 and mutants of the PKM2 tetramer tend to adopt the
T-state conformation in the apo form but prefer an R-state
conformation in the presence of either FBP or an analog of
PEP.
A “seesaw” model in the R-/T-state transition of PKM2
Previous studies have demonstrated that a PKM2 tetramer
in the R-state (active) is more active than that in the T-state
(inactive). Structural comparison indicates that each indi-
vidual monomer of PKM2 adopts similar fold with a root-
mean-squared deviation (rmsd) of less than 0.6 Å for
approximately 430 aligned Cα atoms (Fig. S2C). However,
structure analysis indicates that the PKM2 tetramer under-
goes signiﬁcant changes between R- and T-state confor-
mations with a rotation about the helix α9 of ﬁve degrees for
each monomer (Fig. 2B and 2C). This observation is con-
sistent with previous studies of the PKM protein in Leish-
mania Mexicana (Morgan et al., 2010). The PKM2 tetramer
is formed through intermolecular interactions between four
monomers on large (A-A′) and small (C-C′) interfaces
(Fig. 2A). We propose a seesaw model for overall confor-
mational changes during transitions between the R-state
(PKM2K305Q) and the T-state (PKM2K422R) (Fig. 2B and 2C).
On the C-C′ interface, each monomeric PKM2 adopts a
rigid conformation and rotates alone with strand β20
(Fig. 2B–D). When PKM2 adopts the T-state conformation,
the FBP activation motif (FAM, residues G514–T522) and
helix α18 on monomer A interact with FAM and α18 on
monomer B on one side of two parallel seesaws. Helices
α14/α15 on monomer A and α14/α15 on monomer B are
apart from one another on the other side (Figs. 2D and S3).
In a process of transitioning from the T-state to the R-state,
FAM/α18 on monomer A and FAM/α18 on monomer B move
away from one another, and helices α14/α15 on monomer A
and α14/α15 on monomer B move closer to one another.
Consistent with the above observations, the distance
between residues M525 (β20) on monomer A and M525
(β20) on monomer B is approximately 5.0 Å in either the R-
or T-state tetramer (Table S2). In contrast, the distance
between residues L488 (in α18) on monomer A and L488 (in
α18) on monomer B is ∼25.9 Å in the T-state and ∼27.4 Å in
the R-state conformation, respectively; the distance between
residues E397 (in α14) on monomer A and E397 (in α14) on
monomer B is ∼20.7 Å in T-state and ∼14.0 Å in the R-state
conformation.
On the A-A′ interface, each monomeric PKM2 rotates
alone with helix α9 (Fig. 2E). When PKM2 adopts the R-state
conformation, oxalate is recognized in the active site by
residues R294, G295 and D296 of α8 on monomer A. The
three residues are stabilized by residue R342 of α11 on
monomer C through forming two intermolecular hydrogen
bonds. In the process of an R- to T-state transition, helices
α10/α11/α13 on monomer A move away from α10/α11/α13
on monomer C, whereas helices α14/α15/α16 on monomer
A move closer to α14/α15/α16 on monomer C. The
RESEARCH ARTICLE Ping Wang et al.









conformational change leads to a ﬂip of the side chain on
residue R342 on monomer C, which stabilizes residues
R294/G295/D296 on monomer A in the R-state conforma-
tion. As a result, PKM2 forms an inactive T-state tetramer, in
which oxalate is not well recognized in the active site
(Fig. 2F). The mutation R342 W of PKM2 abolished its
enzymatic activity, further supporting its signiﬁcance for
catalysis (Fig. S1G). Consistent with above observations,
the distances between residues K311 (in α9) on monomer A
and K311 (in α9) on monomer C are approximate 18.0 Å in
the two states (Table S2). In contrast, the distance between
residues E373 (in α13) on monomer A and E373 (in α13) on
monomer C is ∼37.8 Å in the T-state and ∼31.1 Å in the
R-state conformation; the distance between residues V414
(in α15) on monomer A and V414 (in α15) on monomer C is
∼36.3 Å in the T-state and ∼40.5 Å in the R-state
conformation.
In support of the above conformational changes, the
transition of PKM2 from the R-state to the T-state, the dis-
tance between β20 on monomer A and β20 on monomer C
along with the C-C interface decreases from ∼59.6 Å to
∼53.6 Å, whereas the distance between α9 on monomer A
and α9 on monomer B along with the A-A′ interface increa-
ses from ∼43.4 Å to ∼51.6 Å (Table S2). Regulation of
Table 1. Crystallographic data and structure reﬁnement statistics
Protein PKM2Y105E PKM2K305Q PKM2R399E PKM2K422R PKM2K422R_FBP
Data collection













Space group P 31 P 1 21 1 P 1 21 1 P 1 21 1 P 1 21 1











Total reﬂections 610595 610809 513532 581223 411179
Unique
reﬂections
72016 98003 87781 98424 70893
Multiplicity 8.5 (8.3) 6.2 (6.3) 5.8 (5.8) 5.9 (5.9) 5.6 (5.8)
Completeness
(%)
98.72 (88.38) 99.52 (95.59) 98.30 (84.27) 96.72 (89.08) 98.9 (100)
Mean I/sigma (I) 5.56 (2.87) 11.35 (3.33) 7.34 (3.91) 7.47 (2.93) 35.0 (2.68)
R-sym 0.192 (0.768) 0.098 (0.552) 0.166 (0.83) 0.137 (0.676) 0.084 (0.854)
Structure reﬁnement
R-factor 0.2202 0.2131 0.2101 0.1974 0.2759
R-freeb 0.2652 0.2601 0.2562 0.2397 0.3036
RMS (bonds) 0.010 0.002 0.002 0.002 0.005
RMS (angles) 1.39 0.63 0.57 0.60 0.87
Average
B-factor




84.2 91.8 92.2 90.7 93.5
Allowed regions
(%)




1.4 0.3 0.3 0.4 0.4
Disallowed
regions (%)
0.3 0 0.3 0.3 0.3
a The values for the data in the highest resolution shell are shown in parentheses.
b Rfree = ∑Test||Fobs| − |Fcalc||/∑Test |Fobs|, where “Test” is a test set of about 5% of the total reﬂections randomly chosen and set aside
prior to reﬁnement for the structure.
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intermolecular interactions on either the A-A′ (PEP binding
site) or C-C′ (α14/α15 or FAM/α18) interface will lead to an
R-/T-state transition of PKM2 and affect its enzymatic
activity. For example, association of PEP or its analog oxa-
late of PKM2 induces an R-state conformation through
enhancing intermolecular interactions on the A-A′ interface.
In addition, FBP recruits FAM back to the FBP binding
pocket of PKM2 and disrupts the intermolecular interactions
on the C-C′ interface to form an R-state conformation
(Fig. 2B and 2C).
PKM2K305Q disrupts tetramer formation and impairs
enzymatic activity
PKM2K305Q adopts a similar R-state conformation to that of
PKM2Oxalate with a rmsd of 0.48 Å for 1750 aligned Cα atoms
(Fig. 3). The existence of malonate in the condition of crystal-
lization may lead to an active R-state conformation of
PKM2K305Q (Fig. S2B). No signiﬁcant conformational change
was observed for the two compared structures (Fig. S2A).
However, differences exist between PKM2K305Q and
PKM2Oxalate. In the PKM2Oxalate structure, two hydrogen bonds
are formedbetween (1) residuesK305 (on helixα9ofmonomer
C)andE384 (onhelixα13) onmonomerAand (2)K305and I35
(close to helix α1) onmonomer A (Fig. 3). The hydrogen bonds
facilitate the intermolecular interactions on the A-A′ interface.
No such contact was observed in PKM2K305Q structure.
The FBP binding pocket on the C-C′ interface of
PKM2K305Q are structurally similar to that of PKM2Oxalate.
Consistently, the enzymatic activity of PKM2K305Q could be
slightly elevated by FBP (Fig. 1C). Gel-ﬁltration and thermal-
shift assays demonstrated that FBP retains its ability to
stabilize PKM2K305Q and promote its dimer formation
(Figs. 1D, 1E and S1E). Altogether, mutation K305Q or
acetylation of residue K305 inhibits PKM2 activity through
hindering the tetramer formation on A-A′ interface.
PKM2K422R forms a tetramer in the T-state in the absence
of FBP and the R-state in the presence of FBP
Different from PKM2Oxalate or PKM2K305Q, PKM2K422R
adopts a T-state conformation in the absence of FBP and an
R-state conformation in the presence of FBP (Fig. S2A). In
the PKM2Oxalate structure, two hydrogen bonds are formed
between residue K422 (on monomer C) and residues P403
and Y444 (on monomer D), whereas FAM is ﬂexible and
invisible (Fig. 3). In the PKM2K422R structure, residue K422R
on monomer C forms two hydrogen bonds with residue E418
on monomer D. Intermolecular interactions are mediated by
hydrogen bonds between residue D487 on α18 of monomer
C and W515 and R516 on FAM of monomer D, and hydro-
phobic interactions between residues W482, W515 and
P517 on both monomer C and monomer D. The FBP
association stabilizes the FAM and disrupts the interactions
between FAM on monomer C and α18 on monomer D,
therefore allowing the tetramer to adopt an R-state confor-
mation (Fig. 3).
The PKM2K422R tetramer is structurally similar to the
PKM2Phe tetramer (PDB: 4FXJ) with a rmsd of 0.41 Å for
1720 aligned Cα atoms (Fig. 4A). Compared to PKM2Phe,
PKM2K422R has two additional hydrogen bonds between
residue K422R on α15 on monomer C and E418 on α15 on
monomer D, which may lead to the dissociation of helices
α14 on monomer C and helices α15 on monomer D, and
therefore strengthen intermolecular interactions (α15 on
monomer C and α15 on monomer D) on the C-C′ interface to
facilitate the T-state tetramer formation. The strong inter-
molecular interactions on the C-C′ interface in PKM2K422R
may be difﬁcult to disrupt by PEP to form an R-state con-
formation. The above structural analyses support the
observations that PKM2K422R forms a less active tetramer in
solution (compared to PKM2WT) but is stable in the thermal-
shift assay (Figs. 1C, 1D and S1E).
Although PKM2K422R tends not to adopt a PEP-induced
R-state conformation because of strong intermolecular
interactions on the C-C′ interface (compared to PKM2Oxalate),
association of FBP did favor the R-state tetramer formation.
Our structure of PKM2K422R_FBP offers direct evidence for
the R-state formation: the PKM2K422R tetramer adopts a
similar fold to that of PKM2WT bound to FBP (PDB: 4B2D)
(Fig. 4B). In support of the above observations, PKM2K422R
showed pyruvate kinase activity comparable to that of
PKM2WT in the presence of FBP, but signiﬁcantly decreased
activity and enhanced cooperativity in the absence of FBP
(Fig. 1C and Table S1).
PKM2R399E tends to inhibit the formation of R-state
tetramer
PKM2R399E also adopts the T-state conformation (Fig. S2A).
No signiﬁcant difference existed between the structures of
PKM2R399E and PKM2Phe (Fig. 4A). Residue R399 of α14 on
Figure 2. Crystal structure of human PKM2 and a “seesaw”
model for conformational transitions of PKM2 tetramer.
(A) Ribbon representation of the human PKM2 structure
(PKM2K422R) with A-A′ (red box) and C-C′ (yellow box)
interfaces indicated as dashed lines. Four monomers are
shown in different colors. (B and C) A “seesaw” model for the
conformational transitions between the R-state (B) and T-state
(C) conformations of the PKM2 tetramer. Critical elements for
the conformational changes are indicated. Dashed arrows
indicate the directions for the rotation of each monomer from
the R- (B) to the T- (C) state. The monomers are indicated as
monomer A to D for simplicity in the following description. (D
and E) A close-up view for the structural comparison of the
PKM2 structure in the R- and T-state conformations on the C-C′
(D) or A-A′ (E) interface. PKM2 in R- and T-state conformations
are colored in yellow and blue, respectively. (F) A structural
comparison of the active site of PKM2 in R- and T-state
tetramers. PKM2 in R- and T-state conformations are colored in
yellow and blue, respectively.
s
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monomer C forms hydrogen bonds with residues E396 of
α14 and E418 of α15 on monomer D on the C-C′ interface of
the PKM2WT structure. However, residue R399E on mono-
mer C may not form the same hydrogen bonds in PKM2R399E
even in the R-state (in the presence of PEP or FBP) because
the three negatively charged residues may repel one another
(Fig. 3). The existence of R399E in PKM2 will inhibit the
formation of the R-state conformation induced by FBP or
PEP, and lead to a decrease of enzymatic activity (compared
to PKM2WT). Consistently, in the presence of FBP,
PKM2R399E is less active and has less of a tendency to form
a tetramer compared to PKM2WT (Fig. 1C and 1E). In con-
trast, no such signiﬁcant difference in the extent of tetramer
formation was observed in the absence of FBP.
PKM2Y105E inhibits FBP association and formation
of the FBP-induced R-state of PKM2
A previous study indicated that phosphorylation of residue
Y105 inhibits FBP association and tetramer formation of
PKM2, and thus decreases its enzymatic activity (Hitosugi
et al., 2009). In the crystal structure, PKM2Y105E binds to
proline, which was derived from a crystallization condition
and might have facilitated a T-state conformation (as did
phenylalanine) (Fig. S2D). No signiﬁcant conformational
change around residue Y105E was observed between
structures of PKM2Y105E and PKM2Oxalate (Fig. 3). The
crystal structure could not reveal the mechanism for the
inhibition of FBP association. However, it is possible that
phosphorylation of Y105 functions during the dynamic tran-
sition, which could not be observed in crystal structure. In
support of this conjecture, PKM2Y105E has similar enzymatic
activity and tetramer formation (compared to PKM2WT) in the
absence of FBP (Fig. 1C and 1D). The addition of oxalate
leads to an increase in tetramer formation to a comparable
extent for PKM2Y105E and PKM2WT (Fig. S1F). In contrast,
the addition of FBP results in signiﬁcantly less of an increase
in the extent of tetramer formation for PKM2Y105E (compared
to PKM2WT) (Fig. 1E). Taken together, the mutation Y105E,
or phosphorylation of residue Y105, inhibits FBP association
and prevents the FBP-induced R-state formation of PKM2.
DISCUSSION
A working model for the dynamic regulation of PKM2
Based on above analyses, here we propose a working
model for the dynamic regulation of PKM2 (Fig. 5). PKM2
exists in a mixed population of monomer, dimer and tetra-
mer, and prefers a T-state conformation if the tetramer forms
in the absence of FBP. Upon FBP association, PKM2
undergoes a change from the T-state to the R-state confor-
mation, which favors the recognition of PEP in the active site
and enhances its pyruvate kinase activity. Regulation of the
intermolecular interactions on the A-A′ or C-C′ interface
plays an important role in conformational changes of PKM2.
A “Rock and Lock” model has been proposed based on
structural studies of pyruvate kinase from L. Mexicana
(Morgan et al., 2010). However, the model was not sufﬁcient
to reveal the mechanism for dynamic regulation of human
PKM2. In this work, a “seesaw” model was proposed based
on the comparison of human PKM2 structures in T- and
R-state tetramers (Fig. 2B and 2C). Our biochemical and
structural studies revealed the mechanisms for dynamic
regulation of the pyruvate kinase activity of PKM2 by inhib-
itor/activator, post-translational modiﬁcations and a patient-
derived mutation (Fig. 5). The two layers of regulation pro-
vide precise control of pyruvate kinase activity of PKM2 in
various biological and pathological conditions.
Post-translational modiﬁcations (such as acetylation and
phosphorylation) and the observed patient-derived mutation
regulate PKM2 pyruvate kinase activity through modulating
tetramer formation or the transition between T- and R-state
conformations (Fig. 5). PKM2 with an acetylated K305
mainly forms a monomer in solution and forms a dimer in the
presence of FBP because the protein loses the intermolec-
ular interactions on the A-A′ interface. The lack of tetramer
formation leads to a signiﬁcant decrease in the enzymatic
activity. Phosphorylation of residue Y105 inhibits FBP
association and prevents the FBP-induced R-state formation
of PKM2, but experiences minor effects in the absence of
FBP. Acetylation of residue K433 was reported to decrease
PKM2 activity through inhibiting FBP association (Lv et al.,
2013). PKM2R399E tends to inhibit the formation of R-state
tetramer (R399E on monomer A repels E396 on monomer A
and E418 on monomer B on the C-C′ interface) and leads to
a decrease of activity even in the presence of FBP. Inter-
estingly, PKM2K422R tends not to form the R-state confor-
mation in the absence of FBP because the hydrogen bonds
between residues K422R on monomer A and E418 on
monomer B on the C-C’ interface favor a stable T-state tet-
ramer formation. Moreover, FBP could induce the re-forma-
tion of the R-state tetramer of PKM2K422R. Thus, PKM2K422R
shows low activity and high cooperativity in the absence of
FBP but comparable activity to that of PKM2WT in the pre-
sence of FBP. Notably, the cellular concentration of PEP
ranges from 4 μmol/L to 140 μmol/L in human and rat tissues
(Liebermeister, 2005). Under such conditions, PKM2K305Q
and PKM2K422R show a signiﬁcant decrease in pyruvate
kinase activity (compared to PKM2WT). Consistently, acety-
lation of K305 on PKM2 changes metabolic intermediates
and promotes cell proliferation and tumor growth, and the
K422R mutation of PKM2 enhances HeLa cell proliferation
(Gupta et al., 2010; Lv et al., 2011).
The pyruvate kinase activity of PKM2 could be regulated
by small molecules. FBP could recruit the FAM to the FBP
binding pocket on the C-C′ interface and facilitate R-state
Figure 3. Structural comparisons of PKM2 mutants and
PKM2Oxalate (in the R-state). Close-up views of PKM2 mutants
with critical residues indicated as stick representations.
PKM2Oxalate (in the R-state) is colored in gray.
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Figure 4. Structural comparisons of PKM2 mutants with PKM2Phe (in T-state) and PKM2K422R_FBP with PKM2 wild type bound
with FBP. (A) Close-up views of PKM2 mutants with critical residues indicated as stick representation. PKM2Phe (in T-state) is
colored in gray. (B) Close-up views of PKM2K422R_FBP with critical residues indicated as stick representation. PKM2FBP (in R-state,
PDB: 4B2D) is colored in gray.
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tetramer formation of PKM2. PEP, or its analog (such as
oxalate, malonate), associates with PKM2 on the A-A′
interface and allosterically induces R-state tetramer forma-
tion. Another PKM2 activator, TEPP-46, enhances the
intermolecular interactions on the A-A′ interface and favors
an R-state conformation (Anastasiou et al., 2012). The
crystal structure of PKM2 bound to phenylalanine demon-
strates that the amino acid could lock PKM2 in an inactive
T-state (Morgan et al., 2013), while the crystal structure of
PKM2 bound to serine demonstrates that the amino acid
could also allosterically activate PKM2 (Chaneton et al.,
2012). SAICAR is a metabolite abundant in proliferating cells
and stimulates both pyruvate and protein kinase activities of
PKM2 (Keller et al., 2012; Keller et al., 2014). PKM2Q393K
(Q393 is located on helix α14) is a SAICAR-insensitive
mutant, suggesting that the compound might regulate PKM2
through both A-A′ and C-C′ interfaces.
PKM2 has long been known to have pyruvate kinase
activity. However, several studies recently indicated that
PKM2 also possesses protein kinase activity, which plays an
important role in tumorigenesis. For example, EGFR-
activated ERK2 promotes nuclear translocation and protein
kinase activity of PKM2 (Yang et al., 2012a; Yang et al.,
2012b). SAICAR directly interacts with PKM2 and promotes
its protein kinase activity (Keller et al., 2014). In addition,
association of tyrosine phosphorylated peptide, acetylation
of residue K433 or the mutation of R399E of PKM2 promotes
its protein kinase activity and nuclear localization, which are
correlated with predominant dimer formation (Gao et al.,
2012; Gao et al., 2013; Lv et al., 2013). Interestingly, these
dimers are formed with the loss of intermolecular interaction
on the C-C′ interface, suggesting that regulation on this
interface may be responsible for the switch from pyruvate
kinase activity to protein kinase activity of PKM2. Further
structural and biochemical studies may reveal the mecha-
nisms for the switch of substrate speciﬁcity of PKM2.
In summary, our study provides structural insight into
dynamic regulation of PKM2 by post-translational modiﬁca-
tions and a patient-derived mutation. The “seesaw” model
reveals the mechanism for the transition between T- and
R-state conformations and provides a platform for further



















Figure 5. Regulation of PKM2 activity by inhibitor/activators, post-translational modiﬁcations and a patient-derived
mutation. PKM2 exists in a mixed population of monomer, dimer and tetramer. Acetylation of residue K305 disrupts the tetramer
formation. Phosphorylation of residue Y105, the patient derived mutation K422R and phenylalanine association induce an inactive
T-state tetramer formation, whereas FBP and serine promote its active R-state formation. The level of pyruvate kinase activity of
PKM2 is indicated by a colored bar, in which gray represents low activity and deep blue represents high activity.
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The atomic coordinates of the PKM2Y105E, PKM2K305Q,
PKM2R399E, PKM2K422R, and PKM2K422R_FBP have been
deposited in the Protein Data Bank with the PDB codes
4QG6, 4QG8, 4QG9, 4QGC, and 4RPP, respectively.
MATERIALS AND METHODS
Protein crystallization
TheORF of humanPKM2was kindly gifted fromKun-liangGuan’s lab
at Fudan University. Procedures for mutagenesis and protein puriﬁ-
cation can be found in the Supplemental Materials. The crystals for
PKM2 mutants were obtained at 18°C by the hanging-drop, vapor-
diffusionmethod bymixing 1 μL protein solution (15–20mg/mL) with 1
μL reservoir solution containing 0.2 mol/L malonate pH 5.0, 20%
PEG3350 (for PKM2K305Q); 0.2 mol/L L-proline, 0.1 mol/L HEPES pH
7.5, 24%PEG1500 (for PKM2Y105E); 0.2mol/L CaAc2, 20%PEG3350
(for PKM2R399E); 0.2 mol/L K2SO4, 20% PEG3350 (for PKM2
K422R);
and 0.1 mol/L sodium chloride, 0.1 mol/L BIS-TRIS propane pH 9.0,
25% PEG 1500 for (PKM2K422R_FBP).
Data collection and structure determination
Crystals were mounted on nylon loops and ﬂash-cooled in a cold
nitrogen stream at 100 K. The data sets were collected at a single
wavelength at the Shanghai Synchrotron Radiation Facility (SSRF)
in China on beamline BL17U. Data were indexed, integrated and
scaled using the HKL2000 program (Otwinowski and Minor 1997).
The structures of PKM2 mutants were determined by molecular
replacement using the monomer of PKM2 wild-type structure (3BJT.
pdb) as a searching model (Christofk et al., 2008b). Details about
structure determination and reﬁnement can be found in Supple-
mental Materials.
Measurement of pyruvate kinase activity
A lactate dehydrogenase (LDH)-coupled pyruvate kinase activity
assay was performed to measure the activity of wild-type PKM2 and
mutants of PKM2 as previously described (Morgan et al., 2013).
Because the reaction was sigmoidal, the reaction rates of PKM2 (in
the absence of FBP) were calculated according to the Allosteric
Sigmoidal Equation. For the reaction rates of PKM2 in the presence
of FBP, we performed the calculation according to Michaelis-Menten
Equation. Details for the pyruvate kinase assay can be found in
Supplemental Materials.
Thermal shift assay and gel ﬁltration assay
The thermal-shift assay and the gel-ﬁltration (Superdex 200, GE
healthcare, 10/300 GL) assay were performed to examine the
thermal stability and tetramer formation of PKM2 proteins. Detailed
descriptions can be found in Supplemental Materials.
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